China Medical announces Phase 3 ruxolitinib trial met primary endpoint

China Medical System (CHSYF) announces that its subsidiaries, Dermavon Holdings, obtained positive results from the phase 3 clinical trial of ruxolitinib cream in patients with mild to moderate atopic dermatitis in China. The phase 3 clinical trial of ruxolitinib cream in patients with mild to moderate AD in China met its primary endpoint, demonstrating that a significantly higher proportion of patients treated with ruxolitinib cream achieved IGA of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo. For the key secondary endpoint, the proportion of patients achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score of treatment with ruxolitinib cream was also significantly higher than placebo, at week 8. In terms of safety, the severity of treatment-emergent adverse events during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, the ruxolitinib cream was safe and well-tolerated.